PTC Therapeutics, Inc. (PTCT) is a publicly traded Healthcare sector company. As of May 21, 2026, PTCT trades at $71.52 with a market cap of $5.82B and a P/E ratio of -28.67. PTCT moved +0.78% today. Year to date, PTCT is -7.48%; over the trailing twelve months it is +50.47%. Its 52-week range spans $34.57 to $87.50. Analyst consensus is strong buy with an average price target of $93.10. Rallies surfaces PTCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
PTC Therapeutics Raises 2026 Revenue Guidance to $750M–$850M After $272.6M Q1 Sales: PTC Therapeutics posted a Q1 GAAP loss of $2.8 million, or $0.03 per share, versus a $0.48 loss expected, and generated $272.6 million in revenue, driven by $124.6 million from Sephience. It raised 2026 product revenue guidance to $750–$850 million and total revenue to $1.08–$1.18 billion, supported by a $1.89 billion cash balance.
| Metric | Value |
|---|---|
| Price | $71.52 |
| Market Cap | $5.82B |
| P/E Ratio | -28.67 |
| EPS | $-2.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $87.50 |
| 52-Week Low | $34.57 |
| Volume | 354 |
| Avg Volume | 0 |
| Revenue (TTM) | $827.11M |
| Net Income | $-186.73M |
| Gross Margin | 0.00% |
13 analysts cover PTCT: 0 strong buy, 10 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $93.10.